Revisions in the draft of the work plan proposed in 2025 to improve China's conditional approval appear more reasonable than a previous draft, although the updates are still underway. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
